首页 | 本学科首页   官方微博 | 高级检索  
     

细胞外基质金属蛋白酶诱导因子在子痫前期及子痫患者胎盘组织中表达的研究
引用本文:Wang YQ,Mi SF,Li J,Wang YL,Shang T. 细胞外基质金属蛋白酶诱导因子在子痫前期及子痫患者胎盘组织中表达的研究[J]. 中华妇产科杂志, 2006, 41(7): 436-439
作者姓名:Wang YQ  Mi SF  Li J  Wang YL  Shang T
作者单位:1. 北京大学第三医院妇产科,100083
2. 北华大学附属医院妇产科
3. 110004,沈阳,中国医科大学第二临床学院妇产科
4. 中国科学院动物研究所生育生殖生物学国家重点实验室
摘    要:目的探讨细胞外基质金属蛋白酶诱导因子(EMMPRIN)在子痫前期及子痫患者胎盘组织中的表达及其与子痫前期及子痫发病的关系。方法采用免疫组化链霉菌抗生物素蛋白-过氧化酶连接法和RT-PCR技术检测不同孕周的44例子痫前期(重度)孕妇(子痫前期组)、38例子痫孕妇(子痫组)和49例正常孕妇(正常妊娠组)胎盘组织中EMMPRIN蛋白及mRNA的表达。结果(1)EMMPRIN蛋白阳性表达:子痫前期组EMMPRIN蛋白表达中度阳性率为18%(8/44),强阳性率为9%(4/44);子痫组EMMPRIN蛋白中度阳性率为21%(8/38),强阳性率为13%(5/38),两组分别比较,差异均无统计学意义(P>0.05)。正常妊娠组EMMPRIN蛋白表达中度阳性率为12%(6/49),强阳性率为82%(40/49),与子痫前期组及子痫组比较,差异均有统计学意义(P<0.001)。(2) EMMPRIN mRNA表达:子痫前期组孕晚期(37~40周)EMMPRIN mRNA为0.342±0.002,子痫组为0.344±0.023,两组比较,差异均无统计学意义(P>0.05)。正常妊娠组孕晚期(37~40周) EMMPRIN mRNA为0.872±0.094,分别与子痫前期组及子痫组比较,差异均有统计学意义(P<0.001)。结论子痫前期及子痫患者胎盘组织中EMMPRIN表达水平下降是子痫前期及子痫发病的重要原因;EMMPRIN可作为子痫前期及子痫发病的一个预测指标。

关 键 词:子痫 先兆子痫 胎盘 基质金属蛋白酶
收稿时间:2005-08-30
修稿时间:2005-08-30

Differential expression of extracellular matrix metalloproteinase inducer in normal placenta and preeclampsia placenta
Wang Yong-qing,Mi Shu-fang,Li Jun,Wang Yan-ling,Shang Tao. Differential expression of extracellular matrix metalloproteinase inducer in normal placenta and preeclampsia placenta[J]. Chinese Journal of Obstetrics and Gynecology, 2006, 41(7): 436-439
Authors:Wang Yong-qing  Mi Shu-fang  Li Jun  Wang Yan-ling  Shang Tao
Affiliation:Department of Obstetrics and Gynecology, Second Affiliated Hospital, China Medical Univercity, Shenyang 110004, China.
Abstract:OBJECTIVE: To study the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in preeclampsia placenta and the relation with preeclampsia attacks. METHODS: Forty-four samples from pregnant women with preeclampsia (preeclampsia group), 38 samples from pregnant women with eclampsia, and 49 samples from normal pregnancies (control group) were obtained. We detected the expression of EMMPRIN in placenta by immunohistochemistry and the expression of EMMPRIN mRNA by RT-PCR. RESULTS: (1) EMMPRIN positive expression: in preeclampsia group, the moderate expression rate was 18% (8/44) and the strong positive rate was 9% (4/44); in eclampsia group moderate positive rate was 21% (8/38) and strong positive rate 13% (5/38). The difference of the two groups was insignificant (P > 0.05). In control group the moderate positive rate was 12% (6/49) and strong positive rate 82% (40/49), the difference from the preeclampsia and the eclampsia groups was significant (P < 0.001). (2) EMMPRIN mRNA expression: in preeclampsia group EMMPRIN mRNA expression in term placenta (37 - 40 gestational weeks) was 0.342 +/- 0.002, and in eclampsia group 0.344 +/- 0.023; the difference between the two groups was insignificant (P > 0.05). In control group EMMPRIN mRNA expression in term placenta (37 - 40 gestational weeks) was 0.872 +/- 0.094, the differences between the control group and preeclampsia and eclampsia groups were both significant (P < 0.001). CONCLUSION: The decrease in the expression of EMMPRIN in placenta is an important cause of preeclampsia onset; expression rate of EMMPRIN may serve as an indicator in predicting preeclampsia.
Keywords:Eclampsia   Pre-eclampsia   Placenta   Matrix metalloproteinases
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号